192 related articles for article (PubMed ID: 36995019)
1. The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention.
Mahapatra S; Jonniya NA; Koirala S; Ursal KD; Kar P
J Biomol Struct Dyn; 2023; 41(22):13509-13533. PubMed ID: 36995019
[TBL] [Abstract][Full Text] [Related]
2. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
Dianat-Moghadam H; Teimoori-Toolabi L
Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505
[TBL] [Abstract][Full Text] [Related]
3. Future applications of FGF/FGFR inhibitors in cancer.
Ghedini GC; Ronca R; Presta M; Giacomini A
Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
[TBL] [Abstract][Full Text] [Related]
4. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
5. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
[No Abstract] [Full Text] [Related]
6. Targeting the fibroblast growth factor receptor family in cancer.
Hallinan N; Finn S; Cuffe S; Rafee S; O'Byrne K; Gately K
Cancer Treat Rev; 2016 May; 46():51-62. PubMed ID: 27109926
[TBL] [Abstract][Full Text] [Related]
7. De-regulated FGF receptors as therapeutic targets in cancer.
Knights V; Cook SJ
Pharmacol Ther; 2010 Jan; 125(1):105-17. PubMed ID: 19874848
[TBL] [Abstract][Full Text] [Related]
8. Advances and challenges in targeting FGFR signalling in cancer.
Babina IS; Turner NC
Nat Rev Cancer; 2017 May; 17(5):318-332. PubMed ID: 28303906
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment.
Liu G; Chen T; Ding Z; Wang Y; Wei Y; Wei X
Cell Prolif; 2021 Apr; 54(4):e13009. PubMed ID: 33655556
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H
J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of FGFR-mediated carcinogenesis.
Ahmad I; Iwata T; Leung HY
Biochim Biophys Acta; 2012 Apr; 1823(4):850-60. PubMed ID: 22273505
[TBL] [Abstract][Full Text] [Related]
12. Recent developments and advances of FGFR as a potential target in cancer.
Xue WJ; Li MT; Chen L; Sun LP; Li YY
Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach.
Presta M; Chiodelli P; Giacomini A; Rusnati M; Ronca R
Pharmacol Ther; 2017 Nov; 179():171-187. PubMed ID: 28564583
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics.
Parish A; Schwaederle M; Daniels G; Piccioni D; Fanta P; Schwab R; Shimabukuro K; Parker BA; Helsten T; Kurzrock R
Cell Cycle; 2015; 14(13):2121-8. PubMed ID: 25950492
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
Hierro C; Rodon J; Tabernero J
Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
Helsten T; Schwaederle M; Kurzrock R
Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133
[TBL] [Abstract][Full Text] [Related]
17. Approaches targeting the FGF-FGFR system: a review of the recent patent literature and associated advanced therapeutic agents.
Herbert C; Lassalle G; Alcouffe C; Bono F
Pharm Pat Anal; 2014; 3(6):585-612. PubMed ID: 25489913
[TBL] [Abstract][Full Text] [Related]
18. The role of fibroblast growth factors and their receptors in prostate cancer.
Kwabi-Addo B; Ozen M; Ittmann M
Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447
[TBL] [Abstract][Full Text] [Related]
19. Non-canonical fibroblast growth factor signalling in angiogenesis.
Murakami M; Elfenbein A; Simons M
Cardiovasc Res; 2008 May; 78(2):223-31. PubMed ID: 18056763
[TBL] [Abstract][Full Text] [Related]
20. FGFR-TKI resistance in cancer: current status and perspectives.
Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]